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Background: While aerobic glycolysis is linked to unconstrained proliferation in cancer, less is known about its
physiological role. Why this metabolic program that promotes tumor growth is preserved in the genome has thus
been unresolved. We tested the hypothesis that aerobic glycolysis derives from developmental processes that
regulate rapid proliferation.
Methods: We performed an integrated analysis of metabolism and gene expression in cerebellar granule neuron
progenitors (CGNPs) with and without Sonic Hedgehog (Shh), their endogenous mitogen. Because our analysis
highlighted Hexokinase-2 (Hk2) as a key metabolic regulator induced by Shh, we studied the effect of conditional
genetic Hk2 deletion in CGNP development. We then crossed Hk2 conditional knockout mice with transgenic
SmoM2 mice that develop spontaneous medulloblastoma and determined changes in SmoM2-driven
tumorigenesis.
Results: We show that Shh and phosphoinositide 3-kinase (PI3K) signaling combine to induce an Hk2-dependent
glycolytic phenotype in CGNPs. This phenotype is recapitulated in medulloblastoma, a malignant tumor of CGNP origin.
Importantly, cre-mediated ablation of Hk2 abrogated aerobic glycolysis, disrupting CGNP development and
Smoothened-induced tumorigenesis. Comparing tumorigenesis in medulloblastoma-prone SmoM2 mice with and
without functional Hk2, we demonstrate that loss of aerobic glycolysis reduces the aggressiveness of medulloblastoma,
causing tumors to grow as indolent lesions and allowing long-term survival of tumor bearing mice.
Conclusions: Our investigations demonstrate that aerobic glycolysis in cancer derives from developmental mechanisms
that persist in tumorigenesis. Moreover, we demonstrate in a primary tumor model the anti-cancer potential of blocking
aerobic glycolysis by targeting Hk2.
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Aerobic glycolysis, the metabolism of glucose to lactate
despite the availability of oxygen, is observed in diverse
cancers, a phenomenon known as the Warburg effect
[1,2]. Indeed, many cancers, including brain tumors, dem-
onstrate increased glucose utilization, suggesting that
glycolytic metabolism may confer a selective advantage* Correspondence: gershont@neurology.unc.edu
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reproduction in any medium, provided the or[3,4]. Less is known about metabolic adaptations during
development. Examining these adaptations is important
because metabolic patterns that support cancerous growth
may derive from genetic programs that evolved to support
developmental growth.
Neurogenesis, like tumorigenesis, requires rapid cellu-
lar proliferation, but under precise control. In human
brain development, over 80 billion cerebellar granule
neurons (CGNs) are generated in the first 6 months of
life. Many of the developmental milestones observed in
the first year of life are directly attributed to proper for-
mation of cerebellar neural circuits involving the granulel Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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of CGNPs, often driven by mutations in neurodevelop-
mental genes, give rise to medulloblastoma, the most
common malignant brain tumor in children [5,6]. We
hypothesized that aerobic glycolysis is integral to the
regulated proliferation of neural progenitors, and that
aerobic glycolysis in cancer may result from the abnor-
mal persistence of metabolic programs that are typically
restricted to development. We therefore investigated the
relationship between glucose metabolism and neural
progenitor function during cerebellar development and
medulloblastoma pathogenesis.
Postnatal neurogenesis in the cerebellum presents an
ideal opportunity to study metabolic dynamics of neuro-
genesis under aerobic conditions. CGNs are the most
numerous cells in the brain, and arise from CGNPs that
proliferate in the external granule cell layer (EGL) in a
wave of neurogenesis that occurs postnatally and lasts
until postnatal day (P) 15 in mice [7]. CGNPs thus pro-
liferate under normoxic conditions, and mouse cerebel-
lum may be sampled at defined time points to include
proliferating neural progenitors or exclusively post-
mitotic neurons. As CGNPs terminally differentiate, they
migrate from the EGL to the internal granule cell layer
(IGL) such that position in the cerebellum corresponds
with differentiation state. CGNPs are readily cultured
and maintain their proliferative behavior in vitro in
serum-free media supplemented with Shh and insulin
[8,9]. If Shh is withdrawn, CGNPs exit the cell cycle and
differentiate – such that after 24 hours in culture with-
out Shh, proliferation is minimal. Importantly, activating
mutations in the Shh pathway have been found in
human medulloblastoma and can recapitulate tumori-
genesis in transgenic mice, including the ND2:SmoA1
and SmoM2 lines that express constitutively active alleles
of Smoothened [5,10-13]. These animal models consist-
ently implicate CGNPs as proximal cells of origin for
Shh-driven medulloblastoma. Here, we examine glucose
metabolism in CGNPs, CGNs and Smoothened-induced,
murine medulloblastomas in order to determine whether
aerobic glycolysis originates in neural development and
whether this metabolic pattern is essential to the patho-
genesis of embryonal cancers of the nervous system.
Methods
Animals
Mice were handled in compliance with the guidelines of
the University of North Carolina Animal Care and Use
Committee. NeuroD2:SmoA1 mice were provided by
Dr James Olson (Fred Hutchinson Cancer Research Cen-
ter, Seattle, WA, USA) and SmoM2 mice (Bl6 back-
ground) were purchased from Jackson Laboratories (Bar
Harbor, ME, USA). hGFAP-cre mice were generously
provided by Dr Eva Anton (University of North Carolina,Chapel Hill, NC, USA); these mice were initially obtained
in the FVB/N background, and were crossed into the Bl6
background at least 10 times. Hk2fl/fl mice were obtained
from the European Mouse Mutant Archive and are docu-
mented on the archive’s website. In brief, these mice
(deposited by Dr Eija Pirinen) harbor LoxP sites at intron
3 and intron 10 of the Hk2 gene, such that exons 4 to 10
are deleted in the presence of cre recombinase. Hk2fl/fl mice
were crossed at least 5 times with Bl6 mice prior to the
experimental breeding. Medulloblastomas were detected
by daily observation for abnormalities of head shape and
movement, and animals were sacrificed at the onset of
tumor symptoms, specifically ataxia, weight loss or move-
ment disorder. For EdU experiments, mouse pups at P10
were injected intraperitoneally (IP) with 50 μl HBSS con-
taining EdU (250 μM; catalogue number A10044; Life
Technologies, Grand Island, NY, USA) and sacrificed after
24 hours. All animal handling and protocols were carried
out in accordance with established practices as described
in the National Institutes of Health Guide for Care and
Use of Laboratory Animals and as approved by the
Animal Care and Use Committee of the University of
North Carolina (IACUC #10-126.0).
Cell culture techniques
CGNP cultures were generated as previously described
[14]. Briefly, cerebella were dissected from P5 mouse
pups, dissociated, and allowed to adhere to culture wells
in DMEM/F12 (catalogue number 11320; Life Technolo-
gies, Grand Island, NY, USA) with 25 mM or 4 mM KCl
as indicated, supplemented with N2 and 5% FCS for
4 hours, after which media were replaced with identical,
serum-free media. For 5.6 mM glucose experiments,
DMEM/F12 was replaced with DMEM low glucose
(catalogue number 11885; Life Technologies, Grand
Island, NY, USA) supplemented with N2 and KCl to
25 mM. Media were replaced every 24 hours with fresh
media. Shh-treated CGNPs were maintained continu-
ously in Shh (0.5 μg/ml, catalogue number 464SH; R&D
Systems Minneapolis, MN, USA). For hypoxia studies,
CGNPs were plated under normoxic conditions and
allowed to adhere overnight in media supplemented with
Shh and N2. Media were then replaced with media that
was preconditioned in a 2% O2 incubator and supple-
mented with Shh and N2 as indicated. CGNPs were then
maintained in a 2% O2 incubator for 24 hours, after
which lysates were rapidly prepared under normoxia.
Where indicated, Myc inhibitor 10058-F4 (catalogue
number 475956; Calbiochem San Diego, CA, USA)
was added to cultures after the first 24 hours, at the
concentrations specified, and cells were harvested
24 hours later. All metabolic measurements were per-
formed on 3 replicate wells for each condition, except
for the NMR studies in Figure 1C,D in which 6
Figure 1 Shh induces aerobic glycolysis in CGNPs. (A) Counts of EdU+ cells, in 3 replicate wells for each condition, confirm that Shh-treated
CGNPs continue proliferation after 48 hours in culture, while vehicle-treated CGNPs exit the cell cycle. (B) Lactate production, glucose uptake and
oxygen consumption rate (OCR) of Shh-treated and vehicle-treated CGNPs are compared, using 3 replicate wells per condition. Measured values
were normalized for cell number and expressed as fold-change relative to vehicle-treated values. Shh increased lactate production (P < 0.01) and
glucose uptake (P < 0.03) while no statistically significant effect on the OCR was detected. (C) NMR spectra (representative examples on top;
below is orthogonal partial least squares discriminant analysis comparison of 6 replicates of each condition) demonstrate differential
accumulation of lactate in media of Shh-treated CGNPs compared with vehicle-treated CGNPs. The loading coefficient is plotted as the y value,
and the P scaled correlation coefficient is color-coded as indicated. Lactate peaks are deflected toward Shh, indicating greater value in Shh-
treated wells, and color-coded red, indicating statistical significance. (D) Starting with fresh media at time 0, Shh-treated CGNPs used more
glucose (P < 0.001) and produced more lactate (P < 0.001) than vehicle-treated CGNPs over a 6-hour period. Importantly, in Shh-treated CGNPs,
glucose utilization and lactate production were in a stoichiometric 1:2 ratio. Graphs present mean ± standard error of the mean (SEM). Two-tailed
Student’s t test was used for statistical comparisons in (A) and (B), while two-way analysis of variance with Bonferroni correction was used in (D).
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the end of each experiment in order to normalize for
the number of cells per well. For cell counts, cells
were incubated with 1 mM bisbenzimide for 30 min-
utes, photographed through a 20× objective and nuclei
were counted using Leica-Metamorph software (Molecu-
lar Devices Sunnyvale, CA, USA).
In vitro metabolism studies
For enzymatic measurement of lactate, media were
sampled after 48 hours in culture and lactate was quan-
tified by the L-Lactate Assay Kit (catalogue number
1200011002; Eton Bioscience Durham, NC, USA) using
the manufacturer’s protocol. For 18-fluorodeoxiglucose
(18FDG) studies, CGNPs were cultured for 48 hours,
incubated for 40 minutes in 2 μCi 18FDG in glucose-
containing DMEM/F12 supplemented as indicated,
washed twice, and collected. The concentration of FDG
was less than 0.1 nM, and control experiments in which
Shh-treated CGNPs were treated with either normal
media or with media containing 1 nM 2-deoxyglucose
demonstrated no change in lactate production or CGNP
proliferation, measured by incorporation of EdU (data
not shown). Radioactivity was measured by gamma
counter (2470 Wizard2; PerkinElmer Waltham, MA,
USA) and normalized to the activity measured in the ini-
tial media. For oxygen consumption rate (OCR) mea-
surements, after 48 hours in culture with either vehicle
or Shh, CGNPs were changed to fresh media and the
OCR was measured using a Seahorse XF24 (Seahorse
Bioscience, North Billerica, MA, USA) following the
manufacturer’s protocol. The electron transport uncoup-
ling agent trifluorocarbonylcyanide phenylhydrazone
(FCCP; 300 nM) was added, and OCR measurements
were then repeated immediately. For proliferation assays,
EdU was added to the cell culture and visualized using
the manufacturer’s protocol (catalogue number C10337;
Life Sciences), and positive cells were counted using
Leica-Metamorph software (Molecular Devices). For Hk
activity assays, cells from 3 replicate wells per condi-
tion, or snap-frozen cerebella from 3 replicate mice per
genotype, were lysed and processed for colorimetric
assay per manufacturer’s protocol (Hexokinase Assay
Kit, catalogue number E-111; Biomedical Research Ser-
vice Center, SUNY, Buffalo, NY, USA).
For NMR-based metabolomic analysis, cells were pla-
ted in 12-well plates in 650 μl media and then 50 μl
media samples were harvested at the indicated time
points. Cell counts on the day of media harvest demon-
strated that all wells contained 95 to 105% of the mean
number of cells, and there was no statistically significant
variation in cell number in wells treated with Shh or ve-
hicle (data not shown). Media samples were processed
as previously described [15]. Briefly, proton (1H) spectrawere acquired at 25°C on a 14.1 T Varian INOVA spec-
trometer (600 MHz 1H frequency) equipped with a
CapNMR™ microcoil (Magnetic Resonance Microsensors
Corp, Savoy, MN, USA). The 1H spectra were acquired
using a one-pulse sequence with presaturation of the
water resonance using a 90° flip angle, and a total repeti-
tion time of 12.65 seconds. The peak areas in the 1H
spectra were determined using Chenomx NMR proces-
sing software version 7.1 (Edmonton, Alberta, Canada).
First, spectra were zero-filled to 32,000 points, and were
line broadened using a 0.5 Hz exponential Gaussian
function. Chemical shifts presented were obtained from
the Human Metabolome Database [16]. Concentrations
were calculated from the 1H spectra by comparing peak
areas with the peak for 2,20,3,30-duetero-trimethyl propi-
onate. Concentration values were then normalized for
the cell number in each well, and the results were ana-
lyzed by two-way analysis of variance with Bonferroni
correction. For statistical comparison of multiple spec-
tra, we performed orthogonal partial least squares dis-
criminant analysis using ACD Labs 12.0 1D NMR
Processor (ACD Labs Toronto, Ontario, Canada) to
zero-fill to 32,000 points, with a 0.5 Hz exponential
Gaussian function applied, then spectra were binned
into 0.005 ppm segments and values were exported to
SIMCA-P + 11 (Umetrics Umeå, Sweden). Loading coef-
ficients and P-scaled correlation coefficients were
exported to MatLab (Mathworks, Natick, MA, USA)
and plotted as the y value (loading coefficient) and
color coded (correlation coefficient).
In vivo metabolism studies
To measure cerebellar glucose uptake, mouse pups at P5
or P20 were injected IP with 0.2 mCi 18FDG; after
40 minutes, pups were rapidly decapitated and the cere-
bella and forebrain were harvested by dissection. Tissue
samples were washed and weighed, and incorporated
radioactivity was quantified by gamma counter (2470
Wizard2; PerkinElmer). Incorporated counts from the
cerebellum were normalized for tissue weight and for
dose to the brain, as measured by incorporated radio-
activity in the frontal lobe sample from the same animal.
Magnetic resonance spectroscopy (MRS) acquisitions
were performed at 9.4 T on a Bruker BioSpec 94/30
MRI system (Bruker BioSpin, Bilerica, MA, USA). A vol-
ume of interest was placed on the pup cerebellum region
based on T2-weighted images with a size of 11.5 mm3.
A point-resolved spectroscopy sequence was used for
single-voxel signal acquisition (Echo Time = 1.4 ms; total
repetition time = 20,000 ms; 64 × 64 matrix size). The
spectrum was adjusted with the water signal at 4.7 ppm
as a reference.
18FDG positron emission tomography/computed tom-
ography (PET/CT) imaging was performed on a PET/
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Worldwide, Waukesha, WI, USA). Under isoflurane
anesthesia, mice underwent intravenous administration
of 500 μCi 18FDG and computed tomography scan.
Thirty minutes after 18FDG injection, PET/CT imaging
was acquired over 10 minutes. Images were recon-
structed using ordered subset expectation maximization
algorithms, and were normalized to dose and animal
weight to generate standardized uptake values of the
final images.
Histology and immunohistochemistry
Mouse brain and tumor tissue were embedded in paraffin
and sectioned to 5 μm thickness. H & E-stained sections
were prepared using standard techniques. EdU was
detected using the Click-iTW EdU Alexa Fluor 488 Im-
aging Kit (catalogue number C10337; Life Sciences), as
per the manufacturer’s protocol. Immunohistochemistry
(IHC) was performed on paraffin-embedded sections
after deparaffinization in Histoclear, rehydration in a
graded ethanol series, and antigen retrieval by heating to
boiling in 10 mM citrate buffer pH 6.0 in a pressure
cooker for 15 minutes and then transferring to PBS. For
Hk2 detection, tissue was not embedded in paraffin but
rather was sectioned by Vibratome to 100 μm thickness
and stained by IHC without antigen retrieval. IHC was
performed as previously described using primary anti-
bodies: Hk1 (catalogue number 2024; Cell Signaling
Technologies, Danvers, MA, USA), GFP (catalogue
number 600-101-215; Rockland Immunochemicals,
Gilbertsville, PA, USA), Hk2 (catalogue number 2867;
Cell Signaling), Calbindin (catalogue number 2173; Cell
Signaling), CD31 (catalogue number 3528 Cell Signal-
ing), NeuN (catalogue number MAB377; Millipore,
Billerica, MA, USA), proliferating cell nuclear antigen
(PCNA, catalogue number 2586; Cell Signaling), and
p27 (catalogue number 3686; Cell Signaling). After EdU
and IHC staining, nuclei were counterstained with 406-
diamino-2-phenylindole (DAPI; catalogue number
D1306; Life Sciences), diluted 200 ng/ml in PBS for
5 minutes, and immunoreactivity was evaluated with a
Leica epifluorescence DM5000B microscope (Leica Micro-
systems, Wetzlar, Germany). Stained slides were then
scanned using an Aperio ScanScope XT (Vista, CA, USA).
Western blot analysis
Cultured cells, whole cerebella, and tumors were lysed
by homogenization in lysis buffer (catalogue number
9803; Cell Signaling). Protein concentrations were quan-
tified using the Bicinchoninic acid method (catalogue
number 23227; Thermo Scientific Asheville, NC, USA)
and equal concentrations of protein were resolved on
SDS-polyacrylamide gels then transferred to polyvinyli-
dene fluoride membranes. Immunologic analysis wasperformed on a SNAP ID device (Millipore) using the
manufacturer’s protocol with primary antibodies to β-
actin (catalogue number 4970; Cell Signaling), Hk1
(catalogue number 2024; Cell Signaling), Hk2 (catalogue
number 2867; Cell Signaling), Cyclin D2 (catalogue
number 3741; Cell Signaling), insulin-like growth factor
(IGF) receptor (catalogue number 9750; Cell Signaling),
phospho-IGF receptor (catalogue number 6113; Cell Sig-
naling), Akt (catalogue number 4685; Cell Signaling),
pAkt (catalogue number 4060; Cell Signaling), HP-Hif1a
(catalogue number 3434; Cell Signaling), phospho-AMP-
activated kinase (catalogue number 2535; Cell Signaling),
phospho-Acyl-CoA carboxylase (catalogue number 3661;
Cell Signaling), caspase-3 (cC3, catalogue number 9664;
Cell Signaling), GFP (catalogue number 600-101-215;
Rockland), Smo (catalogue number AB72130; Abcam,
Cambridge, MA, USA), and Cip2A (catalogue number
SC-80660; Santa Cruz Biotechnology Santa Cruz, CA,
USA). Secondary antibodies were anti-rabbit IgG horse-
radish peroxidase (catalogue number 7074; Cell Signaling),
and anti-mouse IgG horseradish peroxidase (catalogue
number 7076; Cell Signaling). Antibody conjugates were
visualized by chemiluminescence (catalogue number
RPN2106; GE Healthcare).
Quantitative RT-PCR
Total RNA was prepared from CGNPs using the RNeasy
Mini Kit (catalogue number 74104; Qiagen, Valencia, CA)
as per protocol. First-strand cDNA was synthesized using
the Invitrogen SuperScript III Kit (catalogue number
18080-051, Life Sciences). To prevent amplification from
genomic DNA, PCR primers were designed to span at
least one intron, and PCR products were cloned and
sequenced to verify identity. The PCR primers were:
Hk2, ATTGTCCAGTGCATCGCGGA and AGGTCA
AACTCCTCTCGCCG; Cyclin D2, GCGTGCAGAAG
GACATCCA and CACTTTTGTTCCTCACAGACCTC
TAG; and β-actin, ATGCTCTCCCTCACGCCATC and
CAGGATTCCATACCCAAGA. PCR reactions were
run on an ABI 7500Fast instrument, using ABI Fast
Sybr Green master mix (catalogue number 4385612;
Applied Biosystems Carlsbad, CA, USA), cycling be-
tween 95 and 60°C, as per the manufacturer’s protocol,
for 50 cycles. The threshold cycle (CT) was determined
by ABI proprietary software. PCR efficiency for each
primer pair was measured by amplifying a series of
copy number standards from cloned, sequenced PCR
products and used to calculate the fold-change, using
β-actin as the reference standard [17].
Results
Shh signaling induces aerobic glycolysis in CGNPs
To determine whether mitogenic signaling alters the glu-
cose metabolism of neural progenitors, we compared
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tion of CGNPs cultured in the presence or absence of Shh.
We isolated CGNPs from P5 mouse pups and cultured
them in serum-free, N2-supplemented media, with Shh or
vehicle as indicated. After 48 hours in culture, only Shh-
treated CGNPs continued to proliferate (Figure 1A). Start-
ing from fresh media at 24 hours, from 24 to 48 hours in
culture, Shh-treated CGNPs accumulated 180% more lac-
tate than Shh-deprived CGNPs that exited the cell cycle
(Figure 1B). Shh-induced lactate production did not de-
pend on the high glucose and K+ concentrations of typical
CGNP media, as Shh induced comparable lactate produc-
tion in CGNPs maintained in CGNP media (18 mM glu-
cose, 25 mM KCl), DMEM/F12 (4 mM KCl) or low-
glucose DMEM (5.6 mM glucose; see Additional file 1: Fig-
ure S1). Shh-treated CGNPs also demonstrated differential
uptake of 18FDG when exposed briefly to the tracer in
freshened 18 mM glucose culture media (Figure 1B). Des-
pite increased glucose uptake and lactate production, Shh-
treated CGNPs did not increase the OCR, measured as
picomoles per minute in real-time by an XF Extracellular
flux Analyzer (Seahorse Bioscience) and normalized for the
number of cells per well. Importantly, both vehicle-treated
and Shh-treated CGNPs increased the OCR briskly and
equally when exposed to the respiratory chain uncoupling
agent FCCP (data not shown), indicating that CGNPs were
not constrained by the availability of oxygen. Taken to-
gether, these results demonstrate that Shh induced CGNPs
to increase metabolism of glucose to lactate under condi-
tions in which oxygen was not limiting.
To identify metabolic changes induced by Shh in a
nonbiased approach, we used 1H NMR spectroscopy to
measure metabolite accumulation in media of isolated
CGNPs. NMR allows the simultaneous measurement of
a large number of water-soluble metabolites, including
products of lipid, amino acid and carbohydrate metabol-
ism [15]. We compared media samples, taken at theTable 1 Concentrations of selected metabolites in Shh- or veh
Shh
0 hours (μM) 6 hours (μM) Δ6 hours (μM)
Acetate 109 ± 5 105 ± 2 −4 ± 5
Alanine 160 ± 4 394 ± 4 234 ± 6
Arginine 997 ± 49 1,002 ± 22 5 ± 53
Glucose 196,834 ± 934 17,312 ± 328 −2,372 ± 990
Glutamine 2,443 ± 99 2,037 ± 31 −407 ± 103
Glycine 223 ± 21 221 ± 6 −2 ± 22
Lactate 334 ± 27 4,952 ± 114 4,618 ± 117
Leucine 578 ± 29 483 ± 17 −95 ± 33
Threonine 461 ± 30 484 ± 37 23 ± 47
Valine 558 ± 14 499 ± 21 −59 ± 24indicated times after media change, from Shh-treated
and vehicle-treated CGNPs beginning at 24 hours in cul-
ture. We generated NMR spectra from each of 6
replicate wells for each condition at 0, 2 and 6 hours
after media change, and used orthogonal partial least
squares discriminant analysis to identify metabolites that
varied consistently with the presence or absence of Shh.
This analysis highlighted lactate, glucose and glutamine
as the predominant metabolites altered by Shh treatment
(Figure 1C). We then conducted a more precise statis-
tical analysis by subjecting concentrations of each me-
tabolite at 0 and 6 hours in vehicle and Shh wells to
two-way analysis of variance with Bonferroni correction;
this analysis identified only glucose and lactate as chan-
ging with statistical significance with Shh (Table 1). These
NMR data, demonstrating increased glucose utilization
and lactate production induced by Shh, were consistent
with data from colorimetric lactate detection and 18FDG
studies (Figure 1B). Importantly, Shh induced a change in
glucose concentration (2.3 mM; 0.5 mM/106 cells) that
was one-half of the change in lactate (4.6 mM, 1.0 mM/
106 cells), consistent with the stoichiometric relationship
of 1 molecule of glucose giving rise to 2 molecules of
lactate (Table 1 and Figure 1D). Shh thus exerted a potent
effect on the energy metabolism of CGNPs, and the pri-
mary manifestation of this effect was the induction of aer-
obic glycolysis.
Concentrations of each metabolite were calculated from
NMR spectra, with 6 replicate wells per condition. Data
presented as mean ± SEM. For statistical analysis, two-way
analysis of variance with Bonferroni correction was ap-
plied, and P values were calculated for the contrast of
change in Shh (ΔShh) versus change in vehicle (ΔV).
To determine whether CGNPs utilize glucose through
glycolysis in vivo, we compared glucose utilization and
lactate production in mouse pups of various ages, either
during (P1 to P15) or after (>P15) the period of CGNPicle-containing CGNP media at the indicated times
Vehicle ΔShh vs. ΔV
0 hours (μM) 6 hours (μM) Δ6 hours (μM) P value
111 ± 3 127 ± 7 15 ± 8 >0.05
165 ± 6 348 ± 13 183 ± 15 >0.05
990 ± 16 989 ± 26 −2 ± 30 >0.05
19,449 ± 749 19,399 ± 405 −49 ± 852 <0.001
2,509 ± 92 2,515 ± 65 6 ± 113 >0.05
215 ± 10 254 ± 8 39 ± 13 >0.05
299 ± 15 2,012 ± 49 1,713 ± 51 <0.001
555 ± 23 560 ± 4 5 ± 23 >0.05
413 ± 14 487 ± 14 74 ± 20 >0.05
540 ± 22 552 ± 17 12 ± 28 >0.05
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injecting pups at P5 or P20 with 18FDG IP, harvesting
the cerebella, counting incorporated radioactivity and
normalizing results to tissue weight. We found 30%
greater glucose uptake in P5 cerebella compared with
cerebella from P20 animals (P < 0.02; Figure 2A). Increased
glucose metabolism during the neurogenic period might
be due to increased glycolysis or increased oxidative
phosphorylation. To detect glycolytic activity, we mea-
sured local lactate concentration in vivo using 1H MRS.
P12 pups were better suited for MRS studies than P5
pups because they are larger and still harbor proliferating
CGNPs. We consistently detected lactate, identified as a
doublet at 2.5 ppm, in 3/3 P12 cerebella (Figure 2B)
while no lactate was detected in cerebella from adult
mice (Figure 2B), or in forebrains of P12 pups (data not
shown). Taken together, our in vitro and in vivo bioener-
getic studies demonstrate that Shh activates a glycolytic
phenotype in CGNPs that sharply contrasts the metabolic
pattern of the surrounding brain.Glycolytic phenotype persists in medulloblastoma
Medulloblastoma cells, like CGNPs, are highly prolifera-
tive. To determine whether the high glucose flux
observed in mitotic CGNPs persists in medulloblastoma,
we used 18FDG PET/CT to compare glucose uptake in
tumor-bearing and wild-type mice. We consistently
detected strong glucose uptake within ND2:SmoA1-
induced medulloblastomas (Figure 2C). Elevated glucose
uptake in murine medulloblastoma is consistent with
reported PET scan results in human medulloblastoma
[18] and confirms that medulloblastomas share the
glycolytic phenotype of CGNPs.Figure 2 Glycolytic phenotype is common to CGNPs and medulloblas
CGNP proliferation, than at P20 after neurogenesis was completed, as mea
repeated 3 times using paired littermates at P5 and P20 and data presente
normalize for dose to the brain. (B) 1H MRS consistently demonstrated a la
box shown in the inset. This doublet was not observed in adult cerebella, o
arrowhead) in ND2:SmoA1 mice demonstrated markedly elevated 18FDG u
in 3/3 tumor-bearing mice demonstrated increased glucose uptake and a rHk2 is induced by Shh-pathway activation and persists in
medulloblastoma
Hk enzymes catalyze the first step in glucose metabol-
ism. While there are four homologous Hk genes, Hk1
and Hk2 have been frequently associated with aerobic
glycolysis [4,19]. To identify proteins that mediate the
glycolytic phenotype of CGNPs and medulloblastoma,
we examined the expression of Hk1 and Hk2 in CGNPs,
CGNs, and ND2:SmoA1-induced medulloblastoma.
We found that expression of Hk2 was induced by
exposure of isolated CGNPs to Shh (Figure 3A). In con-
trast, expression of Hk1 was mildly reduced in Shh-
treated CGNPs (Figure 3A). Consistent with the marked
increase in Hk2 expression, Shh also increased the total
Hk capacity of CGNPs (Figure 3B).
Previous investigations have validated Western blot for
Cyclin D2 as a marker of Shh-induced proliferation [20],
and we therefore compared Cyclin D2 and Hk2 in both
isolated CGNPs and in whole cerebellar lysates at pro-
gressive points in postnatal development. Importantly,
Hk2 expression corresponded closely with the expres-
sion of Cyclin D2 (Figure 3A,C) both with exposure to
Shh in vitro, and in vivo throughout the period of post-
natal neurogenesis. Hk2 and Cyclin D2 were expressed
at P6 and P8, and both proteins were down-regulated by
P14, as neurogenesis wanes. Hk2 and Cyclin D2 were
strongly up-regulated in SmoA1-induced medulloblas-
toma. As with CGNPs in vitro, expression of Hk1 varied
inversely with expression of Hk2 (Figure 3C).
To determine whether induction of Hk2 by Shh oper-
ates through transcription regulation, we compared the
abundance of Hk2 mRNA in CGNPs maintained in the
presence or absence of Shh. We prepared cDNA from
four sets of isolated CGNPs maintained with or withouttoma in vivo. (A) Cerebellar glucose flux was higher at P5, during
sured by 18FDG uptake 1 hour after IP injection (P < 0.02). Experiment
d as mean ± SEM. Uptake by forebrain was also measured and used to
ctate doublet in cerebella of P12 pups (n = 3), in voxel defined by the
r forebrain in P12 animals (data not shown). (C) Medulloblastoma (red
ptake on PET/CT, compared with age-matched control (below). PET/CT
epresentative scan is shown.
Figure 3 Specific up-regulation of Hk2 in Shh-treated CGNPs and medulloblastoma. (A) Western blot from isolated CGNPs demonstrates
that exogenous Shh induces Hk2 and Cyclin D2. Hk1 expression decreased slightly with exposure to Shh. (B) Colorimetric assay of total Hk
activity of CGNP lysates demonstrates a statistically significant increase in Hk activity in Shh-treated CGNPs. (C) Western blot from whole cerebella
at indicated days from birth demonstrates temporal expression patterns of Hk1, Hk2 and Cyclin D2 expression. Hk2 and Cyclin D2 were strongly
detected during the period of CGNP proliferation (postnatal day (P6, P8) and down-regulated by the end of cerebellar neurogenesis P14.
Medulloblastoma, like mitotic CGNPs, expressed high levels of Hk2 and Cyclin D2. (D) Quantitative real-time RT-PCR analysis comparing mRNA
expression in Shh-treated CGNPs relative to expression in vehicle-treated CGNPs. Shh induced comparable up-regulation of Hk2 and Cyclin D2.
Dots indicate measured fold-change in replicate experiments, and bars indicate mean. (E) Immunofluorescence demonstrates reciprocal patterns of Hk1
and Hk2 at P7. CGNs of the IGL expressed Hk1, which was not detected in CGNPs of the EGL. In contrast, Hk2 was detected only in the EGL, the site of
CGNPs at P7. In P16 cerebellum, where the EGL region no longer contains CGNPs, Hk2 was not detected. In medulloblastoma-bearing SmoA1 mice, Hk2
expression was widespread throughout the tumor but remained undetectable in the adjacent IGL. All scale bars = 100 μm.
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Hk2, Cyclin D2 and β-actin by quantitative real-time
RT-PCR. We included Cyclin D2 as a known target of
Shh-signaling and β-actin as a loading control. Shh
increased expression of Hk2, driving a fold-change of
10.7 ± 2.6 (mean ± SEM), comparable with the fold in-
crease for Cyclin D2 of 7.5 ± 1.7 (Figure 3D).
To identify the specific cells expressing Hk1 and Hk2,
we examined cerebellar sections using IHC. In the P7
cerebellum, differentiated CGNs residing in the IGL uni-
formly expressed Hk1, while the Hk1 protein was un-
detectable in the entire population of CGNPs throughout
the EGL (Figure 3E, P7 Hk1 panel). In contrast, Hk2 was
expressed evenly throughout the EGL during neurogen-
esis (Figure 3E, P7 Hk2 panel). Hk2 was absent from the
region of the EGL after the CGNP population had com-
pletely migrated to the IGL (Figure 3E, P16 panel), indi-
cating Hk2-expressing cells were specifically the CGNPs.
Importantly, with the development of medulloblastoma,
Hk2 expression resumed (Figure 3E, medulloblastoma
panel). Thus, while undifferentiated cells including
CGNPs and medulloblastoma expressed Hk2, Hk1 was
expressed by their differentiated progeny.
We next examined whether the Shh-induced expres-
sion of Hk2 and concurrent activation of glycolysis were
mediated by mechanisms distinct from previouslydescribed molecular regulators of metabolism. Previous
investigations have demonstrated induction of Hk2 by
Hif1α [21-23] and PI3K signaling [24]. To modulate
Hif1α activity, we cultured CGNPs in normoxic or hyp-
oxic conditions. To modulate activity of PI3K, we
included or withheld insulin from culture media. CGNPs
are typically cultured with insulin-rich N2 supplement in
order to promote survival by activating P13K signaling
mediated through the insulin receptor and the IGF re-
ceptor (IGFr) [9]. Previous work has demonstrated that
24 hours of N2 deprivation effectively blocks activation
of the PI3K pathway in CGNPs without impairing viabil-
ity [25]. By providing or withholding the ligands Shh and
insulin, we were thus able to modulate the Shh and
PI3K pathways without inhibitors. We exposed CGNPs
to vehicle or Shh, with or without N2, under normoxic
or hypoxic conditions, and then measured Hk2 protein
and lactate accumulation after 24 hours (Figure 4A,B).
Induction of Hif1α was confirmed by the detection of
the breakdown product hydroxyprolyl-Hif1α (HP-Hif1α),
and down-regulation of PI3K activity was confirmed by
decreased phospho-IGF receptor (pIGFr) and decreased
phospho-Akt (Figure 4A). In normoxic conditions, Shh
without N2 induced a moderate increase in Hk2, with
only a small increase in lactate production. N2 without
Shh caused a small increase in lactate but did not induce
Figure 4 Shh-induced expression of Hk2 and concurrent
activation of glycolysis. Shh and insulin/ IGF/ PI3K signaling
pathways converge on Myc–Max effector complex to induce Hk2
expression and glycolysis. (A), (B) Isolated CGNPs were maintained
in media with N2, Shh, neither or both. Media were changed after
24 hours in culture, after which 3 replicates per condition were
maintained in normoxia for 24 hours, while 3 replicates per
condition were concurrently subjected to hypoxia. Expression of
Hk2, Hk1, IGFr, pIGFr, Akt, pAkt, and HP-Hif1α were demonstrated by
Western blot (A), and the lactate concentration in media was
quantified by enzymatic assay, presented as mean ± SEM, normalized
for cell number (B). Addition of N2 alone increased Akt
phosphorylation and mildly increased lactate production without
inducing Hk2. Shh alone caused a modest increase in both Hk2 and
lactate production. The combination of Shh and N2, however,
markedly increased Hk2 expression and lactate production,
indicating robust induction of glycolysis. Hypoxia alone induced
near-maximal lactate production in the absence of Shh and N2,
while also inducing moderate Hk2. Addition of Shh alone or N2
alone to hypoxic CGNPs did not further increase lactate, but the
combination of Shh and N2 added to hypoxic CGNPs further
increased both Hk2 and lactate. (C) Western blot analysis
demonstrates that induction of Hk2 was modulated by Myc inhibitor
10058-F4 in isolated CGNPs maintained in Shh and N2. Reduced
induction of Hk2 was dose dependent and paralleled the expression
of Cyclin D2 and of Cip2a, a protein previously identified as down-
regulated by 10058-F4.
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up-regulated Hk2 more than Shh alone, and increased
media lactate with a greater than additive effect. These
data indicate that, in normoxia, the combination of N2
and Shh is needed for maximal Hk2 induction and to
up-regulate the full complement of genes that cooperate
with Hk2 for maximal lactate production. In contrast,
hypoxia alone induced Hk2 and near-maximal glycolysis
in the absence of Shh and insulin. Insulin without Shhdid not augment the induction of Hk2 by hypoxia. These
findings demonstrate that Shh and N2 acted interdepen-
dently to induce glycolysis during cerebellar develop-
ment, through a mechanism distinct from the induction
of glycolysis by hypoxia.
Previous investigation demonstrated that Shh and insu-
lin/IGF/PI3K signaling pathways converge in CGNPs to
activate N-myc [14]. We therefore tested whether N-myc
activity mediated developmental induction of Hk2. To
disrupt N-myc activity and block potential complementa-
tion through C-myc, we treated CGNPs cultured with
Shh and N2 with the Myc inhibitor 10058-F4 [26], which
blocks association with Max, an interaction required for
Myc transcriptional regulation [27]. We then compared
expression of Hk2 with that of Cyclin D2, a marker of
Shh-induced proliferation, and Cip2A, a known myc tar-
get previously demonstrated to be inhibited by 10058-F4
[28,29]. We found 10058-F4 reduced Shh-mediated in-
duction of Hk2, Cip2A and Cyclin D2 in a dose-
dependent manner (Figure 4C). These data implicate
myc–max transcriptional activation in the induction of
Hk2 by the combination of Shh and PI3K signaling.
Hk2 is required for Shh-induced aerobic glycolysis
To test for a causal link between Shh-induced Hk2 ex-
pression and aerobic glycolysis, we examined CGNP
metabolism in Hk2 conditional knockout mice. We
crossed the Hk2-floxed (Hk2fl/fl) mouse line EM:02074
with a hGFAP-cre line that drives cre-mediated
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We chose this specific cre driver because of the high
rate of tumorigenesis when combined with the SmoM2
allele, as described below [31]. The hGFAP-cre;Hk2fl/fl
mice were obtained at expected Mendelian ratios and
were fertile without overt deficits. Western blot
analysis of cerebellar lysates at P7 demonstrated up-
regulation of Hk2 equivalent to wildtype mice in either
the hGFAP-cre or the Hk2fl/fl genotypes, and showed
an absence of Hk2 protein in the hGFAP-cre;Hk2fl/fl
genotype (Figure 5A). We found no change in Hk1 or
Cyclin D2 expression that correlated with Hk2 deletion
(Figure 5A). Consistent with the lack of change in
Cyclin D2 levels, EdU labeling confirmed that deletion
of Hk2 did not markedly reduce CGNP proliferation
(Figure 5B). EdU imaging did, however, reveal focal
disorganization of the EGL (Figure 5B), as discussed
further below.
Importantly, increased glycolysis in response to
Shh was significantly reduced in CGNPs from
hGFAP-cre;Hk2fl/fl mice. We compared lactate pro-
duction in Shh-treated CGNPs isolated either from
hGFAP-cre;Hk2fl/fl mice or from littermate Hk2fl/flFigure 5 Conditional deletion of Hk2 prevents Shh-induced aerobic g
Cyclin D2 expression in cerebellar lysates at P5 from Hk2fl/fl and Hk2+/+ mic
pups for each genotype at each age. (B) EdU incorporation (green) 24 hou
mice without cre (control) or of hGFAP-cre;Hk2fl/fl mice. White arrowhead m
DAPI. Scale bars = 100 μm. (C) Lactate accumulation in media from hGFAP-
Hk2fl/fl mice without cre. Data compiled from 3 replicates per condition an
without cre. Two-tailed Student’s t test was used for statistical comparison.
without cre (control) or of hGFAP-cre;Hk2fl/fl mice. Experiment performed w
only detectable metabolite to be significantly altered by Hk2 deletion (P <controls that lacked the hGFAP-cre transgene.
We found that while Hk2-deficient CGNPs prolifer-
ated in response to Shh, they generated 40% less
lactate than CGNPs from littermates with intact
Hk2 (Figure 5C). NMR analysis of media samples
also demonstrated decreased lactate production
(Figure 5D). Orthogonal partial least squares dis-
criminant analysis identified lactate as the only me-
tabolite to change significantly with deletion of Hk2;
a trend toward decreased glucose utilization with
Hk2 deletion was also detected, but this change was
not statistically significant relative to the overall glu-
cose concentration (data not shown). Genetic dele-
tion of Hk2 thus reduced glycolysis without causing
CGNPs to catabolize alternative energy substrates,
consistent with increasing efficiency of glucose
utilization through oxidative phosphorylation.
Deletion of Hk2 disrupts CGNP development
Although proliferation did not appear to be reduced
by Hk2 deletion, examination of P7 cerebella from
hGFAP-cre;Hk2fl/fl mice revealed focal regions of
disorganization within the grossly normal cerebellarlycolysis. (A) Representative Western blot comparing Hk2, Hk1 and
e with and without hGFAP-cre. Equivalent results were obtained in 5
rs after IP injection demonstrates proliferation in the EGL of Hk2fl/fl
arks focus of ectopic proliferation. Nuclei are counterstained with
cre;Hk2fl/fl CGNPs was markedly reduced compared with CGNPs of
d mean ± SEM values are presented as fold-change relative to control
(D) Representative NMR spectra from media samples of Hk2fl/fl mice
ith 3 replicates and mean ± SEM values presented. Lactate was the
0.02, two-way analysis of variance with Bonferroni correction).
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regular in thickness, in hGFAP-cre;Hk2fl/fl mice we
noted discrete regions of focal thinning or thickening,
abnormal migration, and increased vascularization
(Figures 5B and 6A to H). CGNPs frequently failed to
migrate over the Purkinje cell layer as expected, and
instead accumulated on both sides of the Purkinje
cells (Figure 6A to D) and at times divided and dis-
placed portions the EGL, as in Figure 5B. Import-
antly, small blood vessels, highlighted by CD31
expression, interrupted the EGL of hGFAP-cre;Hk2fl/fl
mice (Figure 6E,F). Within the EGL, deletion of Hk2
disrupted the expected correspondence between radial
position and differentiation. The EGL is typically
comprised of an outer region of proliferating cells
that express PCNA and an inner region of PCNA-
negative cells in the earliest stage of differentiation,
marked by up-regulation of p27 [32]. In the EGL of
hGFAP-cre;Hk2fl/fl mice, however, CGNPs failed to main-
tain the expected correspondence between radial pos-
ition and expression of either PCNA or p27
(Figure 6G,H). Therefore, although motor impairments
were not detected in hGFAP-cre;Hk2fl/fl mice, genetic de-
letion of Hk2 altered the migration, differentiation and
vascularization of progenitors active during postnatal
cerebellar development.Figure 6 Hk2 deletion causes focal disruption of cerebellar developm
as shown by comparison of cerebella with Hk2 deletion (top row) or with
demonstrate focal disorganization of the CGNP lineage in hGFAP-cre;Hk2fl/f
thinning (white arrowhead) and regions in which CGNPs failed to migrate
Yellow arrowhead, ectopic capillary in the EGL. By contrast, the EGL was ev
without cre (B) and CGNPs completed migration across the PC layer (black
demonstrates a collection of PCs surrounded by the IGL in a hGFAP-cre;Hk
arrowhead), containing green autofluorescent red blood cells. (D) The IGL
(E,F) IHC for endothelial marker CD31 (red) demonstrates interruption of H
counterstained with DAPI. (G, H) IHC for PCNA (green) demonstrates the e
demonstrates the internal region of the EGL where CGNPs exit the cell cyc
the EGL is disrupted in Hk2-deficient cerebella, with focal thinning (white a
arrowhead) and complementary change to the p27+ layer. All scale bars =Deletion of Hk2 disrupts medulloblastoma growth
To determine how loss of Hk2 and anticipated disrup-
tion of aerobic glycolysis would impact medulloblastoma,
we bred hGFAP-cre;Hk2fl/fl mice with cre-inducible
SmoM2 mice [13] to derive medulloblastoma-prone
hGFAP-cre;SmoM2 mice with Hk2+/+, Hk2fl/+ or Hk2fl/fl
genotypes. Activation of SmoM2 by hGFAP-cre induced
robust tumorigenesis: 100% of hGFAP-cre;SmoM2;Hk2+/+
mice developed grossly visible occipital expansion by
P12. At P12, no mice demonstrated neurologic deterior-
ation. Over the following days, however, mice developed
discernible neurologic symptoms such that by P20 100%
of mice required euthanasia due to symptomatic medullo-
blastoma. Median survival was 18 days (Figure 7C) with
no sex-linked variation (data not shown). Western blot
analysis demonstrated that while hGFAP-cre and wildtype
mice down-regulated Hk2 by P15, Hk2 was highly
expressed at P15 in hGFAP-cre;SmoM2 Hk2+/+ tumors.
Hk2 was in fact significantly more abundant in SmoM2
tumors than in P7 cerebella from either wildtype or
GFAP-cre mice (Figure 7A). Hk2 protein was absent,
however, from tumors in hGFAP-cre;Hk2fl/fl mice. Total
Hk activity was markedly reduced by Hk2 deletion
(Figure 7B).
In contrast to the rapidly progressive Hk2 wildtype
tumors, medulloblastomas with Hk2 deletion wereent. Hk2 deletion caused focal disruption of cerebellar development
intact Hk2 (bottom row). Representative H & E-stained sections
l mice (A), with regions of focal thickening (black arrowhead) and
over Purkinje cells (PC; black arrows) that were inwardly displaced.
enly layered in an identical region of cerebellum of a Hk2fl/fl mouse
arrows) to the IGL. (C) IHC for PC marker Calbindin (green)
2fl/fl mouse. Also note the presence of an ectopic capillary (yellow
formed appropriately inside the PC layer in Hk2fl/fl mice without cre.
k2-deficient EGL by capillaries (yellow arrowheads). Nuclei are
xternal, proliferative region of the EGL, while IHC for p27 (red)
le and begin to differentiate. The regular separation of layers within
rrowheads) and thickening of the proliferative PCNA+ layer (black
100 μm.
Figure 7 Hk2 deletion blunts aggressiveness of hGFAP-cre;SmoM2-driven medulloblastoma and extends survival. (A) Western blot
comparing expression of Hk2 and Hk1 in mice with indicated genotype at P7 and P15. Expression of Hk2 protein in SmoM2 tumors with Hk2+/+
genotype exceeded the expression of Hk2 in wildtype mice at P7. Hk2 protein was absent in SmoM2 tumors with the Hk2fl/fl genotype. (B)
Comparison of total Hk activity in tumors with the Hk2+/+ or Hk2fl/fl genotype. Two-tailed Student’s t test used for statistical comparison. (C)
Kaplan–Meier curves demonstrate increased event-free survival in hGFAP-cre;SmoM2;Hk2fl/fl mice, compared with hGFAP-cre;SmoM2;Hk2+/+ mice
(P < 0.00002, log-rank test). While 100% (24/24) of hGFAP-cre;SmoM2;Hk2+/+ mice developed symptomatic tumor requiring euthanasia by P20,
30% (4/13) of hGFAP-cre;SmoM2;Hk2fl/fl mice remained alive without symptoms at P100. (D) Western blot for GFP and Smoothened (Smo)
demonstrates expression of SmoM2-YFP fusion protein (arrowhead) in hGFAP-cre;SmoM2 mice with either the Hkfl/fl or the Hk2+/+ genotype. The
SmoM2 allele is detected in the Smoothened blot as a band (arrowhead) that is not present in wildtype P8 cerebella and is of higher molecular
weight than the wildtype protein. (E) IHC for GFP (brown) demonstrates SmoM2-YFP protein in the neoplastic and differentiated regions of
cerebella from hGFAP-cre;SmoM2 mice with either the Hkfl/+ genotype (upper panel) or the Hk2 fl/fl genotype (middle panel). A section of
cerebella from a wildtype mouse, processed in parallel, demonstrated absence of staining with GFP antibody under identical conditions (lower
panel). Nuclei are counterstained blue with hematoxylin. Scale bars = 50 μm.
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hGFAP-cre;SmoM2;Hk2fl/fl mice developed the charac-
teristic occipital expansion that is the first sign of tumor,
median survival was 31 days (P < 0.00002) and 30%
survived event-free to the end of the experiment at
100 days. Importantly, these long-term survivors were
able to breed with wildtype mice to give rise to hGFAP-
cre;SmoM2;Hk2fl/+ progeny that developed malignant
tumors, demonstrating the efficacy of the inherited
SmoM2 and hGFAP-cre alleles. All hGFAP-cre;SmoM2;
Hk2fl/+ mice, like hGFAP-cre;SmoM2;Hk2+/+ mice, diedby P20 (data not shown). Western blot analysis demon-
strated expression of the SmoM2-YFP fusion protein in
both hGFAP;SmoM2;Hk2+/+ and hGFAP;SmoM2;Hk2fl/fl
mice (Figure 7D), while IHC for GFP revealed SmoM2-
YFP expression throughout the cerebella of hGFAP-cre;
SmoM2 mice, both in tumor and in adjacent, differen-
tiated regions, in both the Hk2+/+ and Hk2f/fl genotypes
(Figure 7E). Mosaicism for SmoM2 was not observed
in any GFP-stained sections. Mice with the hGFAP-
cre;SmoM2;Hk2fl/fl genotype thus expressed SmoM2
and developed tumors, but these tumors progressed
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allele of Hk2.
Along with increasing survival time, deletion of Hk2
profoundly altered tumor pathology. As expected, pro-
liferation was minimal in wildtype cerebella at P15,
where CGNPs had completed migration to the IGL
and terminal differentiation into NeuN+ neurons
(Figure 8A, left column). In 100% of hGFAP-cre;
SmoM2;Hk2+/+ or Hk2fl/+ mice, however, the entireFigure 8 Deletion of Hk2 caused specific changes in pathology and p
(A) Comparison of cerebella at P15 from wildtype (wt; left column), hGFAP
(right column) mice. Proliferating cells were visualized by IHC for PCNA (top
(bottom row). Antibodies are visualized in brown, and nuclei are countersta
examined and representative images are presented. (B) IHC for endothelial
deficient medulloblastoma. Nuclei are counterstained with DAPI. (C) Comp
(green) and p27 (red) respectively, in hGFAP-cre;SmoM2;Hk2fl/+ (top row) o
stained sections are provided for reference (left column). Yellow arrowhead
medulloblastoma concentrated around blood vessels, in contrast to the ev
medulloblastoma, tumor cells that were further from the perivascular regio
demonstrates increased phosphorylation of AMP-activated kinase (AMPk) a
reduced expression of proliferation marker Cyclin D2. Decreased abundanc
not induce apoptosis. Scale bars = 1,000 μm (A), 100 μm (B) and 50 μm (C)posterior fossa was filled with PCNA+ tumor cells in
an expanded EGL by P15; a relatively small fraction of
CGNPs migrated to the IGL, ceased proliferation and
expressed NeuN (Figure 8A, middle column). In con-
trast, hGFAP-cre;SmoM2;Hk2fl/fl mice demonstrated a
smaller PCNA+ population in the EGL and a markedly
larger proportion of CGNPs that differentiated to be-
come NeuN+ CGNs in the IGL (Figure 8A, right col-
umn). Therefore, while deletion of Hk2 did not blockathway activation in hGFAP-cre;SmoM2-driven medulloblastoma.
-cre;SmoM2;Hk2fl/+ (middle column) and hGFAP-cre;SmoM2;Hk2fl/fl
row) and differentiated neurons were labeled by IHC for NeuN
ined blue with hematoxylin. At least 3 tumors of each genotype were
marker CD31 (red) demonstrates increased capillary density in Hk2-
arison of proliferation and early differentiation using IHC for PCNA
r hGFAP-cre;SmoM2;Hk2fl/fl (bottom row) medulloblastoma. H & E-
s highlight blood vessels. Proliferating tumor cells in Hk2fl/fl
en distribution of proliferating cells in Hk2fl/+ tumors. In Hk2fl/fl
n were PCNA– and p27+, indicating cell cycle exit. (D) Western blot
nd Acyl-CoA Carboxylase (Acc1) in Hk2fl/fl medulloblastoma, along with
e of cC3 in Hk2fl/fl medulloblastoma demonstrates that loss of Hk2 did
.
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proliferation caused by SmoM2, as SmoM2-expressing
CGNPs with Hk2 deletion exited the cycle in vastly
greater numbers. Importantly, progenitors in hGFAP-
cre;SmoM2;Hk2fl/fl mice that exited the cell cycle pro-
ceeded with the migration and terminal differentiation
typical of the CGNP lineage, generating a relatively
normal cerebellar architecture.Hk2 links energy metabolism and maintenance of an
undifferentiated state
Along with increased differentiation, Hk2-deficient tumors
demonstrated increased micro-vascularization (Figure 8B)
and increased localization of proliferative cells along blood
vessels (Figure 8C). Between regions of perivascular prolif-
eration, tumor cells exited the cell cycle and up-regulated
the early differentiation marker p27 (Figure 8C). The
close correlation between proliferation and distance
from capillaries suggested that sustained proliferation
in Hk2-deficient tumors might depend on availability
of oxygen. Accordingly, reduced tumor growth might
result from inability to meet energy needs outside the
perivascular region.
To probe for a link between impaired energy production
and reduced tumor growth in Hk2-deficient medulloblas-
toma, we compared phosphorylation of AMPk in cerebella
from hGFAP-cre;SmoM2;Hk2+/+ mice and hGFAP-cre;
SmoM2;Hk2fl/fl mice. At P15, cerebella from both geno-
types expressed SmoM2, but hGFAP-cre;SmoM2;Hk2+/+
cerebella were almost entirely replaced by tumor while
hGFAP-cre;SmoM2;Hk2fl/fl cerebella contained both
tumor and differentiated tissue. We integrated the AMPk
results with a comparison of proliferation and apoptosis
by Western blot analysis for specific markers (Figure 8 F).
AMPk functions as an intracellular energy sensor, becom-
ing phosphorylated in response to cellular energy scarcity
[33]. In Hk2-deficient medulloblastomas, phosphorylation
of AMPk was greatly increased, consistent with energy
scarcity. Phosphorylation of Acc1, a known target of
AMPk [34], was also increased, indicating that the
detected increase in AMPk activity was functionally
relevant. We examined cC3 because we have previously
found that medulloblastomas demonstrate continuous
baseline apoptosis demonstrable with cC3 staining [35].
Interestingly, both Cyclin D2 and cC3 were markedly less
abundant in Hk2fl/fl medulloblastomas, demonstrating
that while energy scarcity correlated with reduced prolif-
eration, it did not provoke cell death. Deletion of Hk2 thus
reduced the ability of progenitors to remain undifferenti-
ated without altering survival. Taken together, these find-
ings support a model in which: 1) aerobic glycolysis
supports the undifferentiated progenitor phenotype of
medulloblastoma by preserving energy homeostasis; and2) impaired energy homeostasis caused by Hk2 deletion
promotes differentiation, both disrupting patterning in de-
velopment and reducing tumor growth.Discussion
Since its initial observation by Otto Warburg, aerobic gly-
colysis has been documented in a variety of cancer cells
and in non-neoplastic thymocytes [36]. The selective ad-
vantage of aerobic glycolysis in cancer has been directly
tested by comparing growth rates of xenograft tumors with
and without PkM2 [37] or Hk2 [4]. Why cells should har-
bor a genetic program that promotes cancer growth, how-
ever, has been unclear. Our data demonstrate that aerobic
glycolysis is a developmental program that is co-opted in
the course of in vivo tumorigenic transformation. Import-
antly, we identified Hk2 as a key mechanism through which
developmental signaling molecules induce aerobic glycoly-
sis. Moreover, the Hk2-dependent, glycolytic metabolism of
mitotic CGNPs was maintained in medulloblastoma and
was essential to cancer pathogenesis: disrupting glycolysis
through conditional deletion of Hk2 markedly reduced
tumor growth while increasing differentiation. These find-
ings reveal cancer cells exploiting the specialized energy
metabolism of developmental progenitors to maintain an
undifferentiated state and malignant potential.
We noted that Hk2 up-regulation exerted profound
effects on glucose metabolism in CGNPs that exceeded the
change in Hk activity measured in lysates. Our data indi-
cate that Hk2 is required for maximal glycolysis, and func-
tions optimally to shunt glucose toward glycolysis in the
intact cell. Hk2 is known to localize to the outer mitochon-
drial membrane, and this subcellular localization is critical
to its pro-glycolytic effect [38]. Accordingly, it is not sur-
prising that the measured effect of increased Hk2 in lysates
underestimates the influence of Hk2 on glucose metabol-
ism in live cells.
The nature of the benefit that glycolysis confers on
dividing cells is controversial. Since oxidative phosphor-
ylation generates more ATP per glucose molecule, an
open question is why cells metabolize any glucose to lac-
tate when oxygen is not limiting [39]. Potential cellular
benefits of aerobic glycolysis for mitotic cells may in-
clude supplying intermediaries for lipid and nucleic acid
synthesis [1], or enabling high glucose flux [39]. High
glucose flux has been observed to exert an anti-
apoptotic effect through diverse mechanisms including
Bax inactivation [40], prevention of cytochrome c release
[41], or redox inactivation of cytochrome c [42]. Our
findings that genetic deletion of Hk2 disrupted both
energy homeostasis and the balance between prolifera-
tion and differentiation provide new insight into the
question of how aerobic glycolysis can support progeni-
tor function.
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ance of self-renewal capacity that allows daughter cells
to remain proliferative after cell division. In the course
of developmental CGNP proliferation, the capacity for
self-renewal is gradually lost and the CGNP population
declines until proliferation ceases. In contrast, under the
influence of SmoM2-driven tumorigenesis, self-renewal
is maintained and the EGL grows unconstrained. Hk2
deletion disrupted the maintenance of self-renewal
capacity, causing premature differentiation of CGNPs in
the EGL, manifested as focal disorganization. In medul-
loblastoma, however, where self-renewal capacity does
not typically wane, Hk2 deletion caused a much greater
effect, disrupting unconstrained growth, promoting
increased differentiation and increasing the probability
of animal survival. The abnormal migration patterns of
Hk2-deleted CGNPs and the reduced growth of Hk2-
deleted tumors thus consistently highlight a role for
Hk2-driven glycolysis in maintaining the undifferenti-
ated progenitor state.
The increased vascularity of Hk2-deleted EGL and
medulloblastoma implicate oxygen homeostasis in progeni-
tor function. By up-regulating Hk2-dependent glycolysis,
wildtype CGNPs reduce oxygen dependence at the cost of
increased utilization of glucose (Figure 1). By blocking
Shh-driven glycolysis, Hk2 deletion increased the depend-
ence of CGNPs and medulloblastoma on vascular support.
The ectopic capillaries formed in the Hk2-deficient EGL
(Figure 6) and the tumor cells in Hk2fl/fl medulloblastoma
that proliferated along capillaries (Figure 7), both demon-
strated increased vascular dependence caused by loss of
Hk2. In Hk2-deficient cerebella, increased vascularity ef-
fectively compensated for the loss of aerobic glycolysis and
cerebellar development was largely preserved despite local
failures of migration and differentiation. In Hk2-deficient
medulloblastomas, however, increased vascularization was
insufficient to compensate, perhaps due to the increased
tumor mass or alternatively due to increased metabolic de-
mand. Importantly, vascular compensation did not prevent
cellular energy scarcity, as demonstrated by activation of
AMPk. Therefore, with increased vessel support, oxidative
phosphorylation could meet the energy needs of develop-
mentally regulated neurogenesis, but not of unconstrained
tumor growth. Importantly, the consequence of energy fail-
ure in medulloblastoma was a loss of progenitor state and
progression through developmentally appropriate differen-
tiation. Similarly, recent investigation has demonstrated
that AMPk activation blocks the reprogramming of mouse
embryonic fibroblasts into induced stem cells [43]; in each
case, activation of AMPk blocks the maintenance of pro-
genitor self-renewal and promotes terminal differentiation.
An important benefit of aerobic glycolysis for CGNPs
may be to prevent energy failure that could limit prolif-
erative potential. Neural stem cells of the forebrain andhippocampus are known to require the support of a
perivascular niche [44-47]. In contrast to these discrete
sites of postnatal neurogenesis, the EGL, where CGNPs
proliferate, extends over a broad area; to achieve even
growth throughout the EGL, CGNPs must proliferate at
a constant rate regardless of distance from the support-
ive niche. Aerobic glycolysis, through reduced oxygen
dependence at the cost of increased glucose dependence,
may reduce the need for perivascular support. While
oxygen must be obtained from capillaries, glucose can
be mobilized from intracellular stores or provided by
neighboring cells through active transport. Aerobic gly-
colysis may thus release progenitors from the perivascu-
lar niche, and disrupting Hk2 may inhibit tumorigenesis
by constraining progenitors to regions of niche support.
Consistent with an integral role in neurogenesis, we
found aerobic glycolysis to be regulated by developmen-
tal signaling. In particular, we found that induction of
glycolysis requires co-incident activation of Shh and in-
sulin/IGF/PI3K pathways. Importantly, we identified
Myc–Max-mediated transcriptional regulation as a spe-
cific downstream effector necessary for this regulation.
Such a role, would be consistent with previous investiga-
tions that have linked c-myc to the Warburg effect in
other cell types [48,49]. Modulation of intracellular cal-
cium has also been identified as a point of convergence
for Shh and PI3K signaling [50] and could play a key
role in mediating Shh effects on CGNP glycolysis.
Alongside our finding that Shh regulates carbohydrate me-
tabolism, recently published work has demonstrated that
Shh down-regulates fatty acid oxidation in favor of lipid
biosynthesis [51]. Importantly, we found that blockade of
Shh pathway-induced glycolysis in medulloblastoma
caused both reduced proliferation and inactivation of Acc1,
a critical regulator of lipid metabolism. These findings to-
gether define a mitogen-induced metabolic configuration
in which carbohydrate and lipid metabolism are integrated
to optimally support progenitor proliferation.
Conclusions
Our results demonstrate that aerobic glycolysis is pri-
marily a neurodevelopmental program that is co-opted
in medulloblastoma tumorigenesis to promote neoplastic
growth. We found that medulloblastoma and neural pro-
genitors share specific metabolic requirements that dis-
tinguish them from post-mitotic brain cells. Our results
showing increased survival in medulloblastoma-bearing
mice with Hk2 deletion have revealed an unexpected
link between cellular metabolism and differentiation
state. In Hk2-deleted tumors where Shh-driven glycoly-
sis was prevented, the consequence was increased differ-
entiation and reduced tumor growth. Together, these
findings connect developmental signaling pathways
with patterns of metabolism in cancer while also
Gershon et al. Cancer & Metabolism 2013, 1:2 Page 16 of 17
http://www.cancerandmetabolism.com/content1/1/2demonstrating the potential efficacy of metabolic therapy
for medulloblastoma through targeting of Hk2.Additional file
Additional file 1: Figure S1. Induction of lactate production by Shh did
not depend on high glucose or KCl concentration. Comparison of media
lactate concentrations measured by the colorimetric method, from
CGNPs cultured in DMEM/F12, supplemented with N2 plus vehicle or
Shh, and KCl as indicated, and from CGNPs cultured in indicated typical
or low-glucose media, supplemented with N2 and either vehicle or Shh.
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